Real-world Improvements in Cognitive Symptoms After Eptinezumab Treatment in Patients in Whom ≥1 Prior Anti-CGRP Preventive Treatment had Failed: 6-month Results for the Ongoing INFUSE Study (P1-15.006)

Q: What does this research mean for the field?

Eptinezumab treatment leads to real-world improvements in migraine-related cognitive symptoms among patients who have failed at least one prior anti-CGRP preventive treatment. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Emad Estemalik; Richard Lipton; Seema Soni-Brahmbhatt; Stephane Regnier; Susanne Awad; S. Wald Grossman; Michelle Townshend; Amaal Starling

doi:10.1212/wnl.0000000000215494

June 9, 2026Neurology

Real-world Improvements in Cognitive Symptoms After Eptinezumab Treatment in Patients in Whom ≥1 Prior Anti-CGRP Preventive Treatment had Failed: 6-month Results for the Ongoing INFUSE Study (P1-15.006)

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to describe the baseline cognitive symptoms related to migraine and the changes observed during eptinezumab treatment.
Interim analysis of the INFUSE study
Evaluation of cognitive symptoms at baseline and during treatment
Participants had previously failed ≥1 anti-CGRP preventive treatment.
Significant improvements in cognitive symptoms reported after 6 months of eptinezumab treatment.
Noted reductions in cognitive issues previously experienced by patients.
Data supports the efficacy of eptinezumab in this specific patient group.

Implication

Demonstrates cognitive symptoms improvement in migraine patients after eptinezumab, suggesting effective relief from treatment failures.

Abstract

To describe migraine-related cognitive symptoms at baseline and changes observed during eptinezumab treatment in an interim analysis of the INFUSE study.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Estemalik et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f056063 https://doi.org/10.1212/wnl.0000000000215494

View Full Paper

Ask AI

Bookmark

Share

Real-world Improvements in Cognitive Symptoms After Eptinezumab Treatment in Patients in Whom ≥1 Prior Anti-CGRP Preventive Treatment had Failed: 6-month Results for the Ongoing INFUSE Study (P1-15.006)

Key Points

Implication

Abstract

Discussion

Cite This Study

Real-world Improvements in Cognitive Symptoms After Eptinezumab Treatment in Patients in Whom ≥1 Prior Anti-CGRP Preventive Treatment had Failed: 6-month Results for the Ongoing INFUSE Study (P1-15.006)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading